Increasing Supplemental Thyroid Hormone Use among Premature Infants Born at 23 to 32 Weeks' Gestation

ABSTRACT

We assessed the pattern of levo-thyroxine (l-thyroxine) therapy in very premature newborns over a 10-year period. We analyzed the electronic database of a large private neonatal practice group (Pediatrix, Ft. Lauderdale, FL) for 23- to 32-week gestation neonates (n = 96,813) managed during 1997 to 2006. L-thyroxine use was analyzed by birth year and by gestational age (GA). L-thyroxine use increased with decreasing GA (nadir 0.3% at 32 weeks, peak 8.4% at 24 weeks). L-thyroxine supplementation increased 2.6-fold over time among infants ≤26 weeks' GA (3.4% in 1997 to 1999 to 8.7% in 2004 to 2006), but did not change among infants born at ≥29 weeks' GA. The highest rate of l-thyroxine supplementation (12.8%) occurred among 24-week GA infants in 2006. Median age at start of l-thyroxine was 23 days (25 to 75%, 15 to 38 days). Only 2% of treated infants were started on day of life 1. Despite no clear evidence from randomized trials supporting thyroid supplementation, l-thyroxine treatment of very preterm infants has significantly increased over the past decade. As l-thyroxine treatment was not consistent with protocols from published randomized trials, new focused randomized controlled trials are needed.

Hypothyroxinemia - thyroid - premature infant

REFERENCES

• 1 Fisher D A. Thyroid function and dysfunction in premature infants.  Pediatr Endocrinol Rev. 2007;  4 317-328
• 2 Williams F L, Visser T J, Hume R. Transient hypothyroxinaemia in preterm infants.  Early Hum Dev. 2006;  82 797-802
• 3 Den Ouden A L, Kok J H, Verkerk P H, Brand R, Verloove-Vanhorick S P. The relation between neonatal thyroxine levels and neurodevelopmental outcome at age 5 and 9 years in a national cohort of very preterm and/or very low birth weight infants.  Pediatr Res. 1996;  39 142-145
• 4 Lucas A, Morley R, Fewtrell M S. Low triiodothyronine concentration in preterm infants and subsequent intelligence quotient (IQ) at 8 year follow up.  BMJ. 1996;  312 1132-1133 discussion 1133-1134
• 5 Reuss M L, Paneth N, Pinto-Martin J A, Lorenz J M, Susser M. The relation of transient hypothyroxinemia in preterm infants to neurologic development at two years of age.  N Engl J Med. 1996;  334 821-827
• 6 Morreale de Escobar G, Obregon M J, Escobar del Rey F. Role of thyroid hormone during early brain development.  Eur J Endocrinol. 2004;  151(Suppl 3) U25-U37
• 7 Zoeller R T, Rovet J. Timing of thyroid hormone action in the developing brain: clinical observations and experimental findings.  J Neuroendocrinol. 2004;  16 809-818
• 8 Chowdhry P, Scanlon J W, Auerbach R, Abbassi V. Results of controlled double-blind study of thyroid replacement in very low-birth-weight premature infants with hypothyroxinemia.  Pediatrics. 1984;  73 301-305
• 9 Biswas S, Buffery J, Enoch H, Bland M, Markiewicz M, Walters D. Pulmonary effects of triiodothyronine (T3) and hydrocortisone (HC) supplementation in preterm infants less than 30 weeks gestation: results of the THORN trial—thyroid hormone replacement in neonates.  Pediatr Res. 2003;  53 48-56
• 10 van Wassenaer A G, Kok J H, de Vijlder J J et al.. Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks' gestation.  N Engl J Med. 1997;  336 21-26
• 11 Amato M, Pasquier S, Carasso A, Von Muralt G. Postnatal thyroxine administration for idiopathic respiratory distress syndrome in preterm infants.  Horm Res. 1988;  29 27-30
• 12 Vanhole C, Aerssens P, Naulaers G et al.. L-thyroxine treatment of preterm newborns: clinical and endocrine effects.  Pediatr Res. 1997;  42 87-92
• 13 Smith L M, Leake R D, Berman N, Villanueva S, Brasel J A. Postnatal thyroxine supplementation in infants less than 32 weeks' gestation: effects on pulmonary morbidity.  J Perinatol. 2000;  20 427-431
• 14 Valerio P G, van Wassenaer A G, de Vijlder J J, Kok J H. A randomized, masked study of triiodothyronine plus thyroxine administration in preterm infants less than 28 weeks of gestational age: hormonal and clinical effects.  Pediatr Res. 2004;  55 248-253
• 15 Osborn D A. Thyroid hormones for preventing neurodevelopmental impairment in preterm infants.  Cochrane Database Syst Rev. 2001;  (4) CD001070
• 16 Golombek S G, LaGamma E F, Paneth N. Treatment of transient hypothyroxinemia of prematurity: a survey of neonatal practice.  J Perinatol. 2002;  22 563-565
• 17 Laughon M, Bose C, Clark R. Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcomes.  J Perinatol. 2007;  27 164-170
• 18 Williams F L, Simpson J, Delahunty C Collaboration from the Scottish Preterm Thyroid Group et al. Developmental trends in cord and postpartum serum thyroid hormones in preterm infants.  J Clin Endocrinol Metab. 2004;  89 5314-5320
• 19 Rose S R, Brown R S, Foley T American Academy of Pediatrics et al. Update of newborn screening and therapy for congenital hypothyroidism.  Pediatrics. 2006;  117 2290-2303
• 20 van Wassenaer A G, Briët J M, van Baar A et al.. Free thyroxine levels during the first weeks of life and neurodevelopmental outcome until the age of 5 years in very preterm infants.  Pediatrics. 2002;  110 534-539
• 21 Briët J M, van Wassenaer A G, Dekker F W, de Vijlder J J, van Baar A, Kok J H. Neonatal thyroxine supplementation in very preterm children: developmental outcome evaluated at early school age.  Pediatrics. 2001;  107 712-718
• 22 Osborn D A, Hunt R W. Prophylactic postnatal thyroid hormones for prevention of morbidity and mortality in preterm infants.  Cochrane Database Syst Rev. 2007;  (1) CD005948
• 23 Osborn D A, Hunt R W. Postnatal thyroid hormones for preterm infants with transient hypothyroxinaemia.  Cochrane Database Syst Rev. 2007;  (1) CD005945
• 24 vanWassenaer A G, Kok J H. Thyroid function and thyroid hormone requirements of very preterm infants.  Pediadtr Rev Neo Rev. 2000;  1 e116-e121
• 25 La Gamma E F, van Wassenaer A G, Golombek S G et al.. Neonatal thyroxine supplementation for transient hypothyroxinemia of prematurity : beneficial or detrimental?.  Treat Endocrinol. 2006;  5 335-346